CN102549434A - 叶酸盐靶向的诊断和治疗 - Google Patents

叶酸盐靶向的诊断和治疗 Download PDF

Info

Publication number
CN102549434A
CN102549434A CN2010800434602A CN201080043460A CN102549434A CN 102549434 A CN102549434 A CN 102549434A CN 2010800434602 A CN2010800434602 A CN 2010800434602A CN 201080043460 A CN201080043460 A CN 201080043460A CN 102549434 A CN102549434 A CN 102549434A
Authority
CN
China
Prior art keywords
patient
tumor
treatment
folate
tumour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800434602A
Other languages
English (en)
Chinese (zh)
Inventor
C.P.利蒙
R.梅斯曼
D.摩尔金斯特恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Priority to CN201510160314.2A priority Critical patent/CN104857534A/zh
Publication of CN102549434A publication Critical patent/CN102549434A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800434602A 2009-07-31 2010-07-30 叶酸盐靶向的诊断和治疗 Pending CN102549434A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510160314.2A CN104857534A (zh) 2009-07-31 2010-07-30 叶酸盐靶向的诊断和治疗

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23059509P 2009-07-31 2009-07-31
US61/230595 2009-07-31
US34644410P 2010-05-19 2010-05-19
US61/346444 2010-05-19
US35102210P 2010-06-03 2010-06-03
US61/351022 2010-06-03
PCT/US2010/043992 WO2011014821A1 (en) 2009-07-31 2010-07-30 Folate-targeted diagnostics and treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510160314.2A Division CN104857534A (zh) 2009-07-31 2010-07-30 叶酸盐靶向的诊断和治疗

Publications (1)

Publication Number Publication Date
CN102549434A true CN102549434A (zh) 2012-07-04

Family

ID=43529728

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800434602A Pending CN102549434A (zh) 2009-07-31 2010-07-30 叶酸盐靶向的诊断和治疗
CN201510160314.2A Pending CN104857534A (zh) 2009-07-31 2010-07-30 叶酸盐靶向的诊断和治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510160314.2A Pending CN104857534A (zh) 2009-07-31 2010-07-30 叶酸盐靶向的诊断和治疗

Country Status (13)

Country Link
US (2) US20120128587A1 (enExample)
EP (1) EP2460013A4 (enExample)
JP (1) JP2013501224A (enExample)
KR (1) KR20120050462A (enExample)
CN (2) CN102549434A (enExample)
AU (1) AU2010278734A1 (enExample)
BR (1) BR112012002064A2 (enExample)
CA (1) CA2769754A1 (enExample)
IL (1) IL217744A0 (enExample)
IN (1) IN2012DN01708A (enExample)
NZ (1) NZ598145A (enExample)
RU (1) RU2012105641A (enExample)
WO (1) WO2011014821A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109475558A (zh) * 2016-05-25 2019-03-15 普渡研究基金会 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
SG190245A1 (en) 2010-11-12 2013-06-28 Endocyte Inc Methods of treating cancer
US20140030321A1 (en) * 2011-04-12 2014-01-30 Endocyte, Inc. Solid pharmaceutical composition
KR102575825B1 (ko) 2012-11-15 2023-09-06 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
JP6595463B2 (ja) 2013-10-16 2019-10-23 ユニベルシテ リブレ デ ブリュッセル 気道に影響する増殖性疾患の処置に有用な製剤
MY194484A (en) 2013-10-18 2022-11-30 Deutsches Krebsforsch Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer
MX2016006219A (es) 2013-11-14 2016-10-28 Endocyte Inc Compuestos para tomografia por emision de positrones.
US11162937B2 (en) 2013-11-19 2021-11-02 Purdue Research Foundation Patient selection method for inflammation
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
EP3242556A1 (en) * 2015-01-11 2017-11-15 Endocyte, Inc. Cancer imaging agent
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
CN110678204A (zh) * 2016-03-29 2020-01-10 恩多塞特公司 用于靶向肿瘤相关巨噬细胞的叶酸缀合物
US10940112B2 (en) 2016-05-04 2021-03-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
KR20210003135A (ko) 2018-04-17 2021-01-11 엔도사이트, 인코포레이티드 암의 치료 방법
WO2020236808A1 (en) 2019-05-20 2020-11-26 Endocyte, Inc. Methods for preparing psma conjugates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071754A2 (en) * 2004-12-23 2006-07-06 Purdue Research Foundation Positron emission tomography imaging method
CN101111267A (zh) * 2004-12-21 2008-01-23 尼克塔治疗亚拉巴马公司 稳定的聚合物巯基试剂
CN101175757A (zh) * 2005-03-16 2008-05-07 恩多塞特公司 蝶酸及其缀合物的合成和纯化

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR042942A1 (es) * 2003-01-27 2005-07-06 Endocyte Inc Conjugados de administracion de drogas de union de receptores de vitaminas
WO2006105141A1 (en) * 2005-03-30 2006-10-05 Purdue Research Foundation Method for cancer prognosis using cellular folate vitamin receptor quantification
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
WO2008051525A2 (en) * 2006-10-25 2008-05-02 Schering Corporation Methods of treating ovarian cancer
US9138484B2 (en) * 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101111267A (zh) * 2004-12-21 2008-01-23 尼克塔治疗亚拉巴马公司 稳定的聚合物巯基试剂
WO2006071754A2 (en) * 2004-12-23 2006-07-06 Purdue Research Foundation Positron emission tomography imaging method
CN101175757A (zh) * 2005-03-16 2008-05-07 恩多塞特公司 蝶酸及其缀合物的合成和纯化

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER P. LEAMON等: "Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC 140 and EC145", 《INT. J. CANCER》 *
DOWNS等: "A Prospective Randomized Trial of Thalidomide with Topotecan Compared With Topotecan Alone in Women With Recurrent Epithelial Ovarian Carcinoma", 《CANCER》 *
RONALD E. FISHER等: "Exploratory Study of 99mTc-EC20 Imaging for Identifying Patients with Folate Receptor-Positive Solid Tumors", 《J NUCL MED》 *
YAP等: "Beyond chemotherapy: targeted therapies in ovarian cancer", 《NATURE REVIEWS CANCER》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109475558A (zh) * 2016-05-25 2019-03-15 普渡研究基金会 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法
CN114903890A (zh) * 2016-05-25 2022-08-16 普渡研究基金会 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法

Also Published As

Publication number Publication date
EP2460013A4 (en) 2013-04-03
US20120128587A1 (en) 2012-05-24
CA2769754A1 (en) 2011-02-03
EP2460013A1 (en) 2012-06-06
IN2012DN01708A (enExample) 2015-06-05
IL217744A0 (en) 2012-03-29
KR20120050462A (ko) 2012-05-18
WO2011014821A1 (en) 2011-02-03
JP2013501224A (ja) 2013-01-10
RU2012105641A (ru) 2013-09-10
CN104857534A (zh) 2015-08-26
AU2010278734A1 (en) 2012-02-23
US20140140925A1 (en) 2014-05-22
BR112012002064A2 (pt) 2017-05-09
NZ598145A (en) 2014-10-31

Similar Documents

Publication Publication Date Title
CN102549434A (zh) 叶酸盐靶向的诊断和治疗
KR102378288B1 (ko) Pet-영상화 면역조정제
Liu et al. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model
CN110312517A (zh) 促黄体激素释放激素受体(lhrh-r)缀合物及其用途
JP2017503763A (ja) Ｇｃｃ発現細胞を撮像するための化合物及び組成物
CN118852044A (zh) 一种肽脲素衍生物、含其的药物组合物及其应用
EP2795317B1 (en) Composition for use in a method for cancer selection
AU2022384793A1 (en) Combination therapy for treating lung cancer
US20240131206A1 (en) Peptide receptor radionuclide therapy
CN118891066A (zh) 用于癌症治疗和成像的复合物
HK1172952A (en) Folate-targeted diagnostics and treatment
US20240050597A1 (en) Radiolabelled alpha-v beta-3 and/or alpha-v beta-5 integrins antagonist for use as theragnostic agent
EP3597224B1 (en) Pigment-coupled mannosyl serum albumin complex and lymph node-probing composition comprising same
WO2023164769A1 (en) Radiopharmaceutical and methods
CN114989256A (zh) 一种放射性同位素标记的分子探针及其制备方法与应用
WO2025251001A1 (en) N-(2-(-2-cyano-4-fluoropyrrolidin-1-yl)-2-oxoethyl)quinoline-4-carboxamide tracer and uses in pet imaging
CN118742332A (zh) 放射性药物和方法
AU2015203646A1 (en) Folate-targeted diagnostics and treatment
DE112011105133T5 (de) Octapeptid zur Herstellung von radiopharmazeutischen Mitteln, das auf dessen Basis hergestellte Arzneimittel und Diagnoseverfahren von Somatostatin-Rezeptor exprimierenden Tumoren
MX2008002843A (es) Metodos para usar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(met ilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftitridin-3-c arboxilico para tratamiento de cancer.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1172952

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120704

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1172952

Country of ref document: HK